Table 3.

Genotype and allele frequencies of IL5−746 C/T, IL6−572C/G and IL13−1112C/T polymorphisms in patients with Graves' disease, Hashimoto's disease and in control subjects.

				Graves' disease			Hashimoto's disease
		Genetic producibility	Control	Intractable	In remission		Severe	Mild
IL5	TT	(Low)	39 (42·9%)	27 (47·4%)	25 (64·1%)		20 (50·0%)	27 (50·9%)
−746	CT		42 (46·2%)	24 (42·1%)	12 (30·8%)	n.s.†	20 (50·0%)	22 (41·5%)	n.s.‡
	CC	(High)	10 (10·9%)	6 (10·5%)	2 (5·1%)		0 (0%)	4 (7·6%)
	T allele	(Low)	120 (65·9%)	78 (68·4%)	62 (79·5%)§	n.s.‡	60 (75·0%)	76 (71·7%)	n.s.‡
	C allele	(High)	62 (34·1%)	36 (31·6%)	16 (20·5%)		20 (25·0%)	30 (28·3%)
IL6	CC	Low	58 (66·7%)	28 (51·9%)	25 (48·1%)		25 (48·1%)	36 (64·3%)
−572	CG	High	25 (28·7%)	26 (48·1%)	21 (40·4%)	P = 0·0357†	22 (42·3%)	18 (32·1%)	n.s.‡
	GG	High	4 (4·6%)	0 (0%)	6 (11·5%)		5 (9·6%)	2 (3·6%)
	CC	Low	58 (66·7%)	28 (51·9%)	25 (48·1%)	n.s.†	25 (48·1%)	36 (64·3%)	n.s.‡
	CG + GG	High	29 (33·3%)	26 (48·1%)	27 (51·9%)¶		27 (51·9%)¶	20 (35·7%)
	C allele	Low	141 (81·0%)	82 (75·9%)	71 (68·3%)	n.s.†	72 (69·2%)	90 (80·4%)	n.s.‡
	G allele	High	33 (19·0%)	26 (24·1%)	33 (31·7%)		32 (30·8%)	22 (19·6%)
IL13	CC	Low	53 (77·9%)	41 (85·4%)	19 (63·3%)		25 (75·8%)	23 (67·6%)
−1112	CT		14 (20·6%)	7 (14·6%)	9 (30·0%)	P = 0·0386†	8 (24·2%)	11 (32·4%)	n.s.‡
	TT	High	1 (1·5%)	0 (0%)	2 (6·7%)		0 (0%)	0 (0%)
	C allele	Low	120 (88·2%)	89 (92·7%)	47 (78·3%)	P = 0·009†	58 (87·9%)	57 (83·8%)	n.s.‡
	T allele	High	16 (11·8%)	7 (7·3%)	13 (21·7%)	OR = 3·52	8 (12·1%)	11 (16·2%)
					(1·31–9·41)

Analysed by χ² tests; OR, odds ratio (95% confidence intervals); n.s., not significant.

^†Intractable Graves' disease (GD) versus GD in remission;

^‡severe Hashimoto's disease (HD) versus mild HD;

^§P = 0·0289, OR = 2·00 (1·06–3·70) (versus control);

^¶P = 0·0306, OR = 2·16 (1·07–4·36) (versus control).